Hyperlinks to databases below
Babiceanu_DatasetBanned_DatasetKnown_FusionsONGene DatabaseBushman Cancer Gene Database
Tumor Gene Set By UniprotOesophagus_DatasetGliomas_DatasetProstate_DatasetPancreases_Dataset
GTExKlijn_DatasetFimereli_Dataset Literature Cortex_Dataset

Link to Genecards:



The fusion gene pair RET--PTC3 information is not available in COSMIC database.


The fusion gene pair RET--PTC3 information is not available in CHIMERKB (CHIMERDB 3.0) database.


The fusion gene pair RET--PTC3 information is available in CHIMERPUB (CHIMERDB 3.0) database.

Fusion_pairTranslocationPMIDDiseaseValidationGene TypeSentence_highlight
RET_PTC3- 16595592papillary carcinoma FISH;PCR;RT-PCR - real-time RT-PCR to quantify RET/PTC1, RET/PTC3, and c-RET transcripts.
RET_PTC3- 7529046- FISH;PCR - The fusion event corresponding to the rearrangement reciprocal to that leading to the formation of RET/PTC3 was also identified and characterized. /// "This previously uncharacterized gene is fused with the tyrosine kinase (tk) domain of the RET proto-oncogene to generate the oncogenic sequence RET/PTC3, thus providing a third example of RET oncogenic activation in papillary thyroid carcinomas. " /// The karyotype of two RET/PTC3 positive tumors did not show any evidence of chromosome 10 abnormalities. /// The two genes generating RET/PTC3 are localized in chromosomal band 10q11.2.. /// The data indicate that a cytogenetically undetectable paracentric inversion within 10q11.2 generates RET/PTC3..
RET_PTC3- 26910217- FISH - One tumor with a RET/PTC1 rearrangement and another with RET/PTC3 were identified in the pediatric population (15%). /// "Additionally, we examined the rate of RAS point mutations with real-time polymerase chain reaction and rearrangements of RET/PTC1 and RET/PTC3 in the pediatric group with fluorescence in situ hybridization. "
RET_PTC3- 19495791thyloid cancer FISH;PCR;RT-PCR - Among tumors with split RET signals, 36.4% (4/11) of tumors exhibited detectable messenger RNA of RET/PTC1 or RET/PTC3. /// "FISH DNA probes included RET locus, and PCR primers were designed targeting RET/PTC1 or RET/PTC3. "
RET_PTC3- 22895275thyroid carcinoma FISH - Simultaneous occurrence of PAX8-PPARg and RET-PTC3 rearrangements in a follicular variant of papillary thyroid carcinoma.. /// "In fact, submicroscopic chromosome rearrangements producing RET-PTC3 and PAX8-PPARg chimeric genes were found by interphase fluorescence in situ hybridization. "
RET_PTC3- 10980597- FISH;PCR - Three main rearranged forms of RET have been described: RET/PTC1 and RET/PTC3, which arise from a paracentric inversion and RET/PTC2, which originates from a 10 : 17 translocation.
RET_PTC3- 22136268thyloid cancer FISH - We further observed that in human thyroid cells, mean distance between genes involved in two most common types of RET/PTC, that is, RET and NCOA4 (partners of RET/PTC3) and RET and H4 (partners of RET/PTC1), was 1.08??0.04 and 1.24??0.05??m, respectively.
RET_PTC3- 16772343papillary carcinoma FISH;PCR;RT-PCR - Sixty-five papillary carcinomas were analyzed for RET/PTC1 and RET/PTC3 using five detection methods: standard-sensitivity RT-PCR, high-sensitivity RT-PCR, real-time LightCycler RT-PCR, Southern blot analysis, and fluorescence in situ hybridization.
RET_PTC3- 15737050goitre - - Reverse transcriptase polymerase chain reaction using specific primers for RET/PTC1 and RET/PTC3 fusion genes identified a RET/PTC3 gene rearrangement in the rhabdoid tumor.
RET_PTC3- 22961909thyroid carcinoma - - Our results reinforce the pathogenic role played by RET/PTC1, RET/PTC3, and PAX8-PPARG fusion genes in thyroid tumorigenesis..
RET_PTC3- 24957039thyloid cancer PCR - RET/PTC3 gene rearrangements were identified in 26/30 (86.67 %) cases, and none of the patient in our series had RET/PTC1 gene rearrangements. /// This present study aims at estimating the frequency of RET/PTC1 and RET/PTC3 gene rearrangements in Chennai population and investigating the correlation between RET/PTC gene expressions with clinical parameters. /// Our results indicate that RET/PTC3 gene rearrangements are the most prevalent form of rearrangements in PTCs of Chennai population.. /// Prevalence of RET/PTC1 and RET/PTC3 gene rearrangements in Chennai population and its correlation with clinical parameters.. /// "Thereafter, total RNA was isolated, and quantitative evaluation of RET/PTC1 and RET/PTC3 gene rearrangements by real-time PCR was performed. " /// There was no statistically significant difference observed between positive and negative mutations of RET/PTC3 mRNA expression with clinic pathological parameters.
RET_PTC3- 26575115thyloid cancer - - BRAF V600E and NRAS codon 61 point mutations, RET/PTC1, RET/PTC3, and PAX8/PPAR? gene rearrangements were analyzed in thyroidectomy specimens.
RET_PTC3- 10773666- FISH;PCR;RT-PCR - Three main rearranged forms of RET have been described: RET/PTC1 and RET/PTC3, which arise from a paracentric inversion of the long arm of chromosome 10, and RET/PTC2, which originates from a 10;17 translocation. /// "Among PTCs, 13 (18.8%) showed a RET rearrangement, and 11 (15.9%) of these carried an inversion (RET/PTC1 or RET/PTC3) in more than 10% of the nuclei examined. "
RET_PTC3- 15680400cowden syndrome FISH;PCR;RT-PCR - The two main forms of RET rearrangement in papillary thyroid carcinomas (PTC) arise from intrachromosomal inversions fusing the tyrosine kinase domain of RET with either the H4 (RET/PTC1) or the ELE1/RFG genes (RET/PTC3).
RET_PTC3- 8806700thyroid carcinoma;thyloid cancer PCR;RT-PCR - Now we found a new type of RET rearrangement: By the 5'RACE method we demonstrated in cDNA the fusion of the tyrosine kinase domain of RET with a truncated ELE1 gene shorter than the ELE1 in RET/PTC3. /// Obviously the new and possibly additional ELE/RET fusion molecules might even increase the high prevalence of ELE1/RET rearrangements in thyroid carcinomas of children after the Chernobyl reactor accident..
RET_PTC3- 9192845papillary carcinoma - - The RET/PTC3 oncogene is an activated form of the RET protooncogene, which is frequently rearranged in papillary thyroid carcinoma. /// "RET/PTC3 results from a structural rearrangement between the ELE1 and the RET genes, and it has been observed in both sporadic and radiation-associated post-Chernobyl tumors. " /// "Notably, in all sporadic tumors and in one post-Chernobyl tumor the ELE1/RET recombination corresponded with short sequences of homology (3-7 nt) between the two rearranging genes. " /// Comparison of the breakpoint regions of ELE1 and RET genes involved in the generation of RET/PTC3 oncogene in sporadic and in radiation-associated papillary thyroid carcinomas.. /// "To understand the molecular basis that predisposes RET and ELE1 genes to be recurrent targets of ""illegitimate"" recombination, we examined the genomic regions containing the ELE1/RET breakpoints of six sporadic and three post-Chernobyl tumors in two papillary carcinomas of different origins. "
RET_PTC3- 10597232thyroid carcinoma;papillary carcinoma - - The RET/PTC3 rearrangement is formed by fusion of the ELE1 and RET genes, and is highly prevalent in radiation-induced post-Chernobyl papillary thyroid carcinomas. /// "Such a structure would facilitate formation of RET/PTC3 rearrangements because a single radiation track could produce concerted breaks in both genes, leading to inversion due to reciprocal exchange via end-joining.. " /// We characterized the breakpoints in the ELE1 and RET genes in 12 post-Chernobyl pediatric papillary carcinomas with known RET/PTC3 rearrangement.
RET_PTC3- 10027005- - - The majority showed RET/PTC3 (i.e., ELE/RET rearrangements), including several subtypes.
RET_PTC3- 9315093papillary carcinoma;follicular adenoma PCR;RT-PCR - In the 'spontaneous' tumors, only the papillary carcinomas presented a ret rearrangement (15%:3/20): 1 RET/PTC1, 1 RET/ PTC3 and 1 uncharacterized. /// "(2) in contrast with the results obtained in the Chernobyl tumors, the most frequently observed chimeric gene was RET/PTC1 instead of the RET/PTC3 and (3) all the tumors were negative for RET/PTC2. "
RET_PTC3- 10566678papillary carcinoma PCR;RT-PCR - A strong correlation was observed between the solid-follicular subtype of papillary carcinoma and the RET/PTC3 isoform: 19 of the 24 RET/PTC-positive solid-follicular carcinomas harbored a RET/PTC3 rearrangement, whereas only 5 had a RET/PTC1 rearrangement. /// High prevalence of RET/PTC rearrangements in Ukrainian and Belarussian post-Chernobyl thyroid papillary carcinomas: a strong correlation between RET/PTC3 and the solid-follicular variant..
RET_PTC3- 15502856papillary carcinoma PCR;RT-PCR - The variability in mRNA levels was marked and four carcinoma groups were identified: one lacking RET/PTC rearrangement with balanced RET exon levels similar to those of the normal samples (7/25 cases, 28%), the second (6/25 cases, 24%) with balanced RET expression and very low levels of RET/PTC1, the third with unbalanced RET exons 10-11 and 12-13 expression, high RET/PTC1 levels but no RET/PTC3 (7/25 cases, 28%), and the fourth with unbalanced RET expression, high RET/PTC1 levels and low levels of RET/PTC3 (5/25 cases, 20%). /// "We have analyzed by real-time RT-PCR 25 papillary carcinoma and 12 normal thyroid samples for RET/PTC1, RET/PTC3 and for RET exons 10-11 and 12-13, which are adjacent to the rearrangement site. " /// RET/PTC1 and RET/PTC3 are the markers for papillary thyroid carcinoma. /// "Real-time quantitative RT-PCR identifies distinct c-RET, RET/PTC1 and RET/PTC3 expression patterns in papillary thyroid carcinoma.. "
RET_PTC3- 15671095papillary carcinoma;thyloid cancer PCR;RT-PCR - RET/PTC1 was more common than RET/PTC3 after each dose, comprising 80% of all rearrangements. /// RET/PTC1 and RET/PTC3 were detected by RT-PCR followed by Southern blotting and hybridization with internal oligonucleotide probes.
RET_PTC3- 23327964- PCR - There were 17 (35.4%) cases of RET/PTC1 and 6 (12.5%) of RET/PTC3, with no multiple rearrangements. /// BRAF T1799A mutation and RET/PTC3 rearrangement in patients suggests a poorer prognosis than the negative one. /// The BRAF T1799A mutation and RET/PTC3 rearrangement may strengthen the expression of PDGF-B. /// "The level of PDGF-B expression in BRAF T1799A positive was higher than that in the negative, and the level of PDGF-B expression in RET/PTC3 was higher than that in RET/PTC1 (P < 0.05). "
RET_PTC3- 19765726thyloid cancer PCR - The primary tumor genotype in 217 patients with papillary thyroid cancer was determined for six common somatic genetic alterations (RET/PTC1, RET/PTC3, and NTRK1 rearrangements, and BRAF V600E, KRAS, and NRAS hotspot mutations) by PCR and direct sequencing, and nested PCR.
RET_PTC3- 15456136thyroid carcinoma;follicular adenoma PCR;RT-PCR - The overall frequency of RET/PTC rearrangements in PTC was 14% (12 of 85), including 7 RET/PTC1, 2 RET/PTC3, 1 deltaRFP/RET and 2 apparently uncharacterized rearrangements.
RET_PTC3- 21880806thyroid carcinoma PCR - Residual material from 1056 consecutive thyroid FNA samples with indeterminate cytology was used for prospective molecular analysis that included the assessment of cell adequacy by a newly developed PCR assay and testing for a panel of mutations consisted of BRAF V600E, NRAS codon 61, HRAS codon 61, and KRAS codons 12/13 point mutations and RET/PTC1, RET/PTC3, and PAX8/PPAR? rearrangements.
RET_PTC3- 12457448thyroid carcinoma;papillary carcinoma PCR;RT-PCR - The prevalence of RET/PTC activation in PTC is high and RET/PTC3 is the only type of activation identified in Hong Kong Chinese and is an important genetic event underlying the development of PTC in the population.. /// "The presence of RET/PTC1, RET/PTC2 and RET/PTC3 activation was analyzed by RT-PCR in twenty PTC from adult patients (age range 24-63 years), one PTC from a 12-year-old boy and anaplastic carcinomas in two adult patients. " /// RET/PTC3 was also identified in PTC from the child and one of the two patients with anaplastic thyroid carcinoma. /// Seventeen PTC from adult patients (85%t) were positive for RET/PTC3. /// RET/PTC3 was the only activation of RET proto-oncogene identified in the samples.
RET_PTC3- 15170542- PCR;RT-PCR - We performed reverse transcription-polymerase chain reaction (RT-PCR) for RET/PTC1, RET/PTC2, and RET/PTC3 rearrangements and immunohistochemical staining for the RET gene. /// "RET/PTC rearrangement by RT-PCR was positive in only 2 (9.1%) of the 22 patients, and RET/PTC1 and RET/PTC3 were positive in 1 patient each (4.5%). "
RET_PTC3- 10850426thyroid carcinoma;papillary carcinoma;follicular adenoma - - Moreover, we found the presence of the RET/ELE1 transcript, the reciprocal complementary form of the oncogenic fusion transcript ELE1/RET, in a papillary thyroid carcinoma specimen expressing the RET/PTC3 oncogene, thus demonstrating that the RET promoter is active in those cells after rearrangement.
RET_PTC3- 21498916- PCR;RT-PCR - 42/266 (15.8%) RET/PTC1 and 13/266 (4.9%) RET/PTC3).
RET_PTC3- 20703476thyroid nodule PCR - Overall, 50 mutations were identified (23 BRAF, 4 RET/PTC1, 2 RET/PTC3, 21 NRAS) in the thyroid FNA biopsies.
RET_PTC3- 16181547- PCR;RT-PCR - Among them, 5 cases (7.6%) were RET/PTC1 and 9 cases (13.6%) were RET/PTC3 respectively.
RET_PTC3- 16630482lymphocytic thyroiditis PCR;RT-PCR - Sixty-six papillary thyroid carcinomas (PTC) and thirty-six control cases with frozen and paraffin-embedded tissues were analyzed for the expressions of WT-RET and oncogene RET/PTC1 or RET/PTC3 by nested RT-PCR. /// "(3) Fourteen PTCs (21.2%) expressed RET/PTC, including five cases expressing RET/PTC1 and nine cases expressing RET/PTC3. "
RET_PTC3- 9768676- PCR;RT-PCR - Four of the PTCs contained RET/PTC1, confirmed by sequencing, and none contained RET/PTC2 or RET/PTC3.
RET_PTC3- 8290261thyroid carcinoma;papillary carcinoma - - Finally we provide evidence indicating that the rearrangement leading to the generation of RET/PTC3 occurred in vivo in the original tumor DNA.. /// Molecular characterization of RET/PTC3. /// This novel chimeric oncogene has been designated RET/PTC3.
RET_PTC3- 11786418- - - Whereas the prevalences of RET/PTC1 and RET/PTC3 were almost equal in classic and follicular PTC, all of the TCV-positive cases expressed the RET/PTC3 rearrangement. /// We have expressed the two oncogenes in PC Cl 3 rat thyroid epithelial cells and found that RET/PTC3 is endowed with a strikingly more potent mitogenic effect than RET/PTC1. /// RET/PTC1 and RET/PTC3 are the most prevalent variants. /// "Mechanistically, this difference correlated with an increased signaling activity of RET/PTC3. " /// These findings prompted us to compare RET/PTC3 and RET/PTC1 in an in vitro thyroid model system. /// Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma..
RET_PTC3- 12057919thyroid nodule;papillary carcinoma - - No RET/PTC1 or RET/PTC3 rearrangements were detected in areas of the same tumors that lacked the cytological alterations. /// RET/PTC1 or RET/PTC3 were detected in microscopic foci with papillary carcinoma features in most of the thyroid nodules (five of seven cases).
RET_PTC3- 11443191thyroid nodule;thyloid cancer - - In addition, eight cases with an unknown RET/PTC rearrangement and three cases with the concomitant expression of RET/PTC1 and RET/PTC3 were found. /// The relative frequency of RET/PTC1 and RET/PTC3 in rearranged benign tumors showed no major difference.
RET_PTC3- 17727338thyroid nodule - - To evaluate BRAF(V600E) mutation on consecutive fine-needle aspiration biopsy (FNAB) specimens in order to assess FNAB's usefulness in preoperative papillary thyroid carcinoma (PTC) diagnosis with the contemporaneous analysis of RET/PTC1 and RET/PTC3 rearrangements obtained from ex vivo thyroid nodules.
RET_PTC3- 22481925thyloid cancer - - Thyroglobulin (TG) and thyroid peroxidase (TPO) expression was found to be significantly decreased in tumors, and the lowest level of TPO expression occurred in a tumor harboring both the p.A67GTTF-2 variant and a RET/PTC3 rearrangement..
RET_PTC3- 15876154- PCR;RT-PCR - The prevalence of RET/PTC1, RET/PTC2, and RET/PTC3 has been found to vary between 0% and 20% in most series of sporadic (nonradiation-induced) PTCs analyzed by type-specific reverse transcription-polymerase chain reaction (RT-PCR) alone. /// "RT-PCR was performed to amplify fusion products of RET/PTC1, RET/PTC2, RET/PTC3, and ELKS-RET from frozen tissue of 105 sporadic PTCs. " /// "Of these tumors, 3 involved RET/PTC1 and 4 involved RET/PTC3. " /// "In our study, RET/PTC1, RET/PTC2, and RET/PTC3 oncogenes were found in only 7 of 105 (7%) sporadic PTCs. " /// "RT-PCR was also performed with two different primer sets for RET/PTC1, RET/PTC2, and RET/PTC3 followed by Southern hybridization in the first 62 tumors. " /// "Because the high prevalence of RET rearrangements in Chinese patients was particularly striking, we were prompted to reexamine chimeric transcripts of RET/PTC1, RET/PTC2, and RET/PTC3 using the same experimental designs in a larger number of cases in the same population. "
RET_PTC3- 23888303follicular thyroid carcinoma;thyroid carcinoma - - Ras and BRAF mutations, RET/PTC1, RET/PTC3, and PAX8/PPAR? rearrangements were analyzed.
RET_PTC3- 11861385- - - PP1 prevented the growth of two human papillary thyroid carcinoma cell lines that carry spontaneous RET/PTC1 rearrangements and blocked anchorage-independent growth and tumorigenicity in nude mice of NIH3T3 fibroblasts expressing the RET/PTC3 oncogene. /// "Furthermore, RET/PTC3-transformed cells treated with 5 microM of PP1 lost proliferative autonomy and showed morphological reversion. "
RET_PTC3- 18364248pleural effusion - - We found that a human MPM cell line, EHMES-10, expressed RET/PTC3 oncogenic rearrangement and a large amount of VEGF.
RET_PTC3- 15947106- PCR - Functional clustering of genes with greater than or less than 1.75-fold expression change (86 genes) revealed RET/PTC3-induced regulation of genes with key functions in apoptosis (Ripk3, Tdga), cell-cell signaling (Cdh6, Fn1), cell cycle (Il24), immune and inflammation response (Cxcl10, Scya2, Il6, Gbp2, Oas1, Tap1, RT1Aw2, C2ta, Irf1, Lmp2, Psme2, Prkr), metabolism (Aldob, Ptges, Nd2, Gss, Gstt1), signal transduction (Socs3, Nf1, Jak2, Cpg21, Dusp6, Socs1, Stat1, Stat3, Cish) and transcription (Nr4a1, Junb, Hfh1, Runx1, Foxe1). /// "Genes coding for proteins involved in the immune response and in intracellular signal transduction pathways activated by cytokines and chemokines were strongly represented, indicating a critical role of RET/PTC3 in the early modulation of the immune response.. " /// "For this purpose, microarray analysis was conducted on PCCL3 cells conditionally expressing the RET/PTC3 oncogene. " /// Gene expression profiling 48 h after activation of RET/PTC3 identified a statistically significant modification of expression of 270 genes.
RET_PTC3- 17195637- - - RET rearrangement was detected in 9 (12%): RET/PTC1--5, RET/PTC3--2, unspecified RET/PTC--1 and delta RET/PTC--1.
RET_PTC3- 16405408struma ovarii - - A quite exhaustive molecular analysis of thyroid specific genes and oncogenes provided two interesting findings: the low PDS mRNA expression, which may explain the low hormonal production and the absence of thyrotoxicosis and the presence of a RET/PTC3 rearrangement, which prompts the possibility of a late malignant evolution.. /// RET/PTC3 rearrangement and thyroid differentiation gene analysis in a struma ovarii fortuitously revealed by elevated serum thyroglobulin concentration.. /// "Despite the absence of malignant features, the expression of RET/PTC3 rearrangement was found, raising the possibility of a potential malignant nature of the tumor. "
RET_PTC3- 19956182thyroid carcinoma;papillary carcinoma;breast cancer - - most early cases were solid PTCs with RET-PTC3 rearrangements, later cases were classical PTCs with RET-PTC1 rearrangements.
RET_PTC3- 26722434thyloid cancer - - Here, we firstly find CNTN1 is a new gene which can be regulated by RET/PTC3 (Ret proto-oncogene and Ret-activating protein ELE1) rearrangement gene and the protein level of CNTN1 is increasing in thyroid cancer.
RET_PTC3- 23797723- - - In 60 cases of PTC with 2 to 4 discrete tumor foci, each focus was tested for BRAF, NRAS, HRAS, and KRAS point mutations and RET/PTC1 and RET/PTC3 rearrangements and analyzed for various histopathologic features.
RET_PTC3- 22323563thyloid cancer - - The predominant rearrangement type was RET/PTC3, which is characteristic of human thyroid cancer arising early after Chernobyl-related radioactive iodine exposure. /// "In summary, we establish a model of DSB induction by RE and report for the first time the formation of carcinogenic chromosomal rearrangements, predominantly RET/PTC3, as a result of DSB produced by RE. "
RET_PTC3- 21674964- - - At the same time the frequency of RET/PTC3 rearrangements with the increasing both the latency period and age of patients, significantly decreased. /// "It was established that induction of both, RET/PTC1 and RET/PTC3 rearrangements was present only in carcinoma samples. " /// " A comparative analysis of the expression of both, RET/PTC1 and RET/PTC3 oncogenes in papillary thyroid carcinomas (PTC) of patients from different age groups was carried out. " /// "In conclusion, our data can evidence for the presence of correlation between the age of patients, latency period and induction of RET/PTC3 oncogenes.. "
RET_PTC3- 19785523thyloid cancer PCR - one tissue specimen with RET/PTC1 rearrangement and one with RET/PTC3 rearrangement were used as positive samples.
RET_PTC3- 12114746trabecular adenoma - - RET/PTC1 and RET/PTC3 are the most common types, accounting for >90% of all rearrangements. /// "RET/PTC1 tends to be more common in tumors with typical papillary growth and microcarcinomas and to have a more benign clinical course, whereas RET/PTC3 in some populations shows a strong correlation with the solid variant of papillary carcinoma and more aggressive tumor behavior. "
RET_PTC3- 25333496thyroid nodule;thyloid cancer - - Our aims were to evaluate the diagnostic utility of assessing the presence of BRAF and RAS mutations and RET/PTC1 and RET/PTC3 rearrangements in all cytological categories in an Italian group of thyroid nodule patients assessed prospectively, and to understand whether and which mutation testing might be helpful in cytologically indeterminate nodules.
RET_PTC3- 21403618thyroid carcinoma;papillary carcinoma;thyloid cancer - - Molecular-biological studies of PTC revealed more common RET/PTC1 and RET/PTC3 rearrangements (34.3% of cases), than BRAFV600E mutation (24%cases).
RET_PTC3- 21219595- PCR;RT-PCR - So far, 15 main RET/PTC rearrangements have been described, among which RET/PTC1 and RET/PTC3 are the most common in PTC - especially in radiation-induced tumours. /// Quantitative evaluation of RET/PTC1 and RET/PTC3 rearrangements by real-time PCR was performed by an ABI PRISM?? 7500 Sequence Detection System. /// "In the study, PTC tissues with known RET/PTC1 and RET/PTC3 rearrangements served as a reference standard (calibrator), while ?-actin gene was used as endogenous control. " /// "Our results indicate that RET/PTC1 and RET/PTC3 rearrangements in Hashimoto's thyroiditis, if any, are rather rare events and further investigations should be conducted in order to determine molecular changes, connecting Hashimoto's thyroiditis with PTC.. " /// Assessment of RET/PTC1 and RET/PTC3 rearrangements in fine-needle aspiration biopsy specimens collected from patients with Hashimoto's thyroiditis.. /// No RET/PTC1 and RET/PTC3 rearrangements were found in the examined samples. /// The aim of study was an assessment of RET/PTC1 and RET/PTC3 rearrangements in patients with Hashimoto's thyroiditis. /// "RET/PTC1 and RET/PTC3 are the result of intrachromosomal paracentric inversions in chromosome 10, where RET and the activating genes (H4 and ELE1, respectively) are located. "
RET_PTC3- 24570192thyroid nodule;papillary carcinoma - - PAX8/PPARG and RET/PTC3 rearrangements were detected by qPCR, while BRAF and RAS point mutations were detected by pyrosequencing.
RET_PTC3- 9589668papillary carcinoma PCR;RT-PCR - Among the papillary thyroid carcinomas of 11 patients examined, we have identified 2 containing RET/PTC1, 3 containing RET/PTC2, and 1 containing RET/PTC3 oncogenes.
RET_PTC3- 18304343thyroid carcinoma PCR;RT-PCR - Previous studies have demonstrated that RET/PTC3 signals through Ras and can provoke nuclear translocation of NFkappaB and the downstream release of pro-inflammatory mediators from thyroid follicular cells in vitro and in vivo, making it an ideal target for studies using FTI. /// "Immunoblot analysis was used to confirm the level at which FTI acts on RET/PTC3-expressing cells, and Annexin V/PI staining of cells was used to assess cell death in RET/PTC3-expressing cells co-cultured with FTI. " /// These data suggest that FTI may be applied as an effective inhibitor for RET/PTC3-oncogene induced pro-inflammatory mediators.. /// Rat thyrocytes transfected with RET/PTC3 or vector control cDNA were co-cultured with FTI and examined for inhibition of chemokine expression and secretion measured by RT-PCR and ELISA. /// "The purpose of the current study was to determine if FTI could be used to inhibit the inflammatory activities of a known Ras-activating human oncoprotein, RET/PTC3. " /// Neither RET/PTC3 protein expression nor apoptosis were affected at any dose of FTI investigated. /// "For the studies described here, an in vitro assay was developed to measure FTI inhibition of RET/PTC3 pro-inflammatory effects. " /// RET/PTC3 is a fusion oncoprotein expressed in the thyroid epithelium of patients afflicted with thyroid autoimmune disease and/or differentiated thyroid carcinoma.
RET_PTC3- 22654872thyroid nodule;thyroid carcinoma;thyloid cancer - - Up to now, 13 different types of RET/PTC rearrangements have been reported but the two most common are RET/PTC1 and RET/PTC3. /// "Ionizing radiations are responsible for the generation of RET/PTC rearrangements, as supported by in vitro studies and by the evidence that RET/PTC, and particularly RET/PTC3, are highly prevalent in radiation induced PTC. " /// "RET/PTC3 is usually associated with a more aggressive phenotype and in particular with a greater tumor size, the solid variant, and a more advanced stage at diagnosis which are all poor prognostic factors. "
RET_PTC3- 17464312- - - RET/PTC1 (two out of seven) and RET/PTC3 (one out of seven), which have been shown in large PTC series to comprise together more than 90% of RET/PTC types, were found in <50% of the cases investigated.
RET_PTC3- 18393128thyloid cancer - - RET/PTC1 in 32(31.7%), RET/PTC3 in 21(20.8%), RET/PTC1+RET/PTC3 both in 10(9.9%) patients were found to be positive. /// No statistical difference was found between RET/PTC1 and RET/PTC3.
RET_PTC3- 20840674papillary adenoma;papillary carcinoma;thyroid cancer;thyroid carcinoma PCR;RT-PCR - In contrast, in thyroid carcinomas with single component histology, RET/PTC1 was detected in 11% of PCs and in none of the UCs, and RET/PTC3 was not found in any of the tumours studied. /// "RET/PTC1 was undetectable in both components from all seven composite UCs, and RET/PTC3 was identified in both components of one composite UC. "
RET_PTC3- 12499271thyroid carcinoma;papillary carcinoma - - RET/PTC3-transformed cells-treated ZD6474 lost proliferative autonomy and showed morphological reversion. /// "Finally, it blocked anchorage-independent growth of RET/PTC3-transformed NIH3T3 fibroblasts and the formation of tumors after injection of NIH-RET/PTC3 cells into nude mice. " /// ZD6474 blocked in vivo phosphorylation and signaling of the RET/PTC3 and RET/MEN2B oncoproteins and of an epidermal growth factor (EGF)-activated EGF-receptor/RET chimeric receptor.
RET_PTC3- 11820615papillary carcinoma;thyloid cancer - - We noted a high frequency of RET/PTC3 mutations in a group of Polish children with papillary thyroid carcinoma, regarded as sporadic cancer..
RET_PTC3- 14534528- - - At 3 h after induction of RET/PTC1 or RET/PTC3 expression, there was evidence of PKCepsilon activation. /// "The expression of RET/PTC3(Y541F), which does not interact with PLCgamma, but signals normally through other RET effectors, had no effect on PKCepsilon distribution at any of the time points examined. "
RET_PTC3- 10027006thyroid carcinoma - - Finally, in order to investigate whether tumors induced by RET/PTC3 are more aggressive than those tumors induced by RET/PTC1, we also generated thyroid-targeted RET/PTC3 transgenic mice..
RET_PTC3- 26601537papillary adenoma - - Based on this database a pooled analysis of data on the rates of RET/PTC1, RET/PTC3 and RET/PTC in total was conducted. /// "For rates of RET/PTC1, RET/PTC3 and RET/PTC in total with respect to formed carcinoma striations the following values (pooling, in %) were obtained: sporadic, total--13.2. "
RET_PTC3- 12182064- - - RET/PTC3 seems to be associated with solid/follicular variant PTC and short latency period (it is found more frequently in children) whereas RET/PTC1--with classic PTC variant and long latency.. /// The majority of RET/PTC identified consists of two types which results from the inversion of chromosome 10: RET/PTC1 and RET/PTC3.
RET_PTC3- 11298625- - - One tumour expressed RET/PTC3, one a variant of RET/PTC3, and one RET/PTC1 and WT-RET simultaneously.
RET_PTC3- 17786355- - - In order to contribute to a better comprehension of the genetic basis of this neoplasm's more aggressive behaviour in 17 aneuploid PTCs we performed a comparative genomic hybridization (CGH) analysis, studied the BRAF and RAS mutational status, searched for RET/PTC1 and RET/PTC3 rearrangements and determined their expression profile. /// None of the studied cases presented RET/PTC1 or RET/PTC3 rearrangement.
RET_PTC3- 8562477neuroblastoma - - To verify the role of RET in neuronal differentiation, we introduced into the human neuroblastoma cell line SK-N-BE four versions of the RET oncogene, activated by different mechanisms: RET/PTC1 and RET/PTC3, which are activated by rearrangement with heterologous genes.
RET_PTC3- 10656692thyloid cancer - - On the other hand, RET/PTC3 was detected only 7 days after X-irradiation, and no transcript of RET/PTC2 was detected. /// "On the other hand, RET/PTC3 was induced at a much lower frequency, and no induction of RET/PTC2 was observed. "
RET_PTC3- 16402937follicular adenoma - - RET/PTC1 and RET/PTC3 expression was evaluated by reverse transcriptase-polymerase chain reaction, whereas screening of BRAF (exon 15) and RAS (HRAS, KRAS2 and NRAS) mutations were performed, respectively, by single strand conformation polymorphism and denaturing high-pressure liquid chromatography.
RET_PTC3- 16832789thyroid carcinoma;thyloid cancer;lymphoma - - RET translocation in carcinoma type RET/PTC1 in elderly and RET/PTC3 in children, and expression Ax1 and Gas6 in children were reviewed as well.
RET_PTC3- 26695504thyroid nodule;thyloid cancer - - Mutations for KRAS, HRAS and NRAS and for BRAF and translocations of PAX8/PPAR?, RET/PTC1 and RET/PTC3 were investigated.
RET_PTC3- 26259532papillary carcinoma;thyloid cancer - - In tumorous samples, 86 BRAF (44.2%), 5 NRAS (3.1%), 2 HRAS (1.0%) and 1 KRAS (0.5%) mutations were found, as well as 9 RET/PTC1 (4.6%) and 1 RET/PTC3 (0.5%) translocations.
RET_PTC3- 16015630papillary carcinoma - - Among the patients in these 3 age groups, the prevalence rate of RET/PTC1 was similar, but RET/PTC3 was observed most frequently among patients age < 20 years. /// "When the tumors were grouped further according to histologic subtypes, the prevalence of RET/PTC3 was greater in solid/solid-follicular papillary carcinomas than in classic papillary carcinomas. "
RET_PTC3- 9001272hashimoto thyroiditis PCR;RT-PCR - Using a sensitive and specific reverse transcriptase-polymerase chain reaction (RT-PCR) assay, we found messenger RNA (mRNA) expression for the RET/PTC1 and RET/PTC3 oncogenes in 95% of the Hashimoto's patients studied. /// The newly identified oncogenes RET/PTC1 and RET/PTC3 provide useful and specific markers of the early stages of papillary carcinoma as they are highly specific for malignant cells.
RET_PTC3- 11747322lymphocytic thyroiditis PCR;RT-PCR - Furthermore, using a polyclonal ret antibody, an apical or a diffuse cytoplasmic ret onc protein immunolabelling was observed in the three patients with RET/PTC1 rearrangement and in the three patients with RET/PTC3 rearrangement.
RET_PTC3- 18583418- - - We studied gene expression profiles in two mouse models of human thyroid carcinoma: the Tg-RET/PTC3 (RP3) and Tg-E7 mice. /// Gene expression in RET/PTC3 and E7 transgenic mouse thyroids: RET/PTC3 but not E7 tumors are partial and transient models of human papillary thyroid cancers..
RET_PTC3- 20012784papillary carcinoma - - Screening for BRAF, RET, KRAS, NRAS, and HRAS mutations, as well as RET-PTC1 and RET-PTC3 rearrangements, was performed on paraffin-embedded material from 17 of these dominant nodules.
RET_PTC3- 26367451thyroid nodule;thyroid carcinoma - - We previously tested 15 cases by our standard 7-gene (BRAF, NRAS, HRAS, KRAS, RET/PTC1, RET/PTC3, PAX8/PPARg) mutation panel.
RET_PTC3- 14668719oxyphilic adenoma - - RET hybrid oncogenes (7x RET/PTC1, 1x RET/PTC1L, 2x RET/PTC3, 5 uncharacterized RET/PTCx) were demonstrated in 7 of 27 HCCs, in 0 of 4 oxyphilic FTCs, in 4 of 5 oxyphilic PTCs, in 1 of 2 HCC-UTCs, and in 3 of 16 oxyphilic adenomas.


The fusion gene pair RET--PTC3 information is not available in CHIMERSEQ (CHIMERDB 3.0) database.

ChiTaRS 2.1

The fusion gene pair RET--PTC3 information is not available in CHITARS database.


The fusion gene pair RET--PTC3 information is not available in FARE-CAFE.


The fusion gene pair RET--PTC3 information is not available in TicDB.

TUMOR FUSION Gene Data Portal

The fusion gene pair RET--PTC3 information is not available in TUMOR FUSION Gene Data Portal.


The fusion gene pair RET--PTC3 information is not available in FusionCancer Database.


The fusion gene pair RET--PTC3 information is not available in ConjoinG Database.


Fusion gene RET--PTC3 has not been seen in a healthy sample (RNA-seq data from some samples from 1000 genomes project: Greger et al., Tandem RNA Chimeras Contribute to Transcriptome Diversity in Human Population and Are Associated with Intronic Genetic Variants, Plos One, Aug 2014 ). Therefore this candidate fusion gene has a low probability of being a false positive. [Fusion gene List compiled from FusionCatcher]


Fusion gene RET--PTC3 is not found in a RNA-seq dataset of 18 types of cancers from 600 tumor samples (B. Alaei-Mahabadia et al., Global analysis of somatic structural genomic alterations and their impact on gene expression in diverse human cancers, PNAS, Nov. 2016 )


Fusion gene RET--PTC3 is not found in the list of known false positive fusion genes. The list has been generated from healthy human samples collected from 16 organs from Illumina BodyMap2 RNA-seq database. A candidate fusion gene found in this list has a very high probability of being a false positive. [Fusion gene List compiled from FusionCatcher]


Fusion gene RET--PTC3 is not found in a healthy sample (RNA-seq database of 27 healthy tissues from 95 human individuals). A candidate fusion gene found in this dataset has a very high probability of being a false positive. [Fusion gene List compiled from FusionCatcher]


Fusion gene RET--PTC3 was not found among the fusion genes which have been previously reported/found in non-tumor cell lines, like for example HEK293. The genes which are observed in those list can be considered as non-somatic mutation. [Fusion gene List compiled from FusionCatcher]


The fusion gene pair RET--PTC3 information is not available in Babiceanu_Dataset.


Fusion gene RET--PTC3 is not found in the list of known false positive fusion genes. A candidate fusion gene found in this list has a very high probability of being a false positive. [Fusion gene List compiled from FusionCatcher]


Fusion gene RET--PTC3 has not been found in the list of fusions previously reported or published in scientific articles/reports/books/abstracts/databases, indexed by Google, Google Scholar, PubMed, etc. The list has been manually curated by FusionCatcher software. This label has only the role to answer with YES or NO the question "has ever before a given (candidate) fusion gene been published or reported?". This label does not have in anyway the role to provide the original references to the original scientific articles/reports/books/abstracts/databases for a given fusion gene.[Fusion gene List compiled from FusionCatcher]

ONGene Database

The head gene RET is a known oncogene according to ONGENE database.

The tail gene PTC3 is a known oncogene according to ONGENE database.

Bushman Cancer Gene Database

The head gene RET is cancer associated according to Bushman Cancer Gene database.

The tail gene PTC3 is cancer associated according to Bushman Cancer Gene database.

Tumor Gene Set By Uniprot

The head gene RET is proto-oncogene or tumor suppresor gene according to Uniprot database.
The tail gene PTC3 is not a proto-oncogene or tumor suppresor gene according to Uniprot database.


Fusion gene RET--PTC3 is not found in oesophageal tumors from TCGA samples, which are published here.


Fusion gene RET--PTC3 is not found in the RNA-seq dataset of 272 glioblastomas, published here.


The fusion gene pair RET--PTC3 information is not available in Prostate Dataset (150 prostate tumor RNAs, Robison et al, Integrative Clinical Genomics of Advanced Prostate Cancer, Cell, Vol. 161, May 2015,


Fusion gene RET--PTC3 is not found in pancreatic tumor dataset, published here.


Fusion gene RET--PTC3 has not been found in a healthy sample (GTEx database of healthy tissues (thru FusionAnnotator)). A candidate fusion gene found in this set has a very high probability of being a false positive. [Fusion gene List compiled from FusionCatcher]


The fusion gene pair RET--PTC3 information is not available in Klijn Dataset.


The fusion gene pair RET--PTC3 information is not found in Fimereli_Dataset.


The fusion gene pair RET--PTC3 information is not found in known fusion genelist compiled from literature.


Fusion gene RET--PTC3 is not found in Cortex_Dataset (Fusion genes found in healthy human brains (BA9 prefrontal cortex)) . A candidate fusion gene found in this dataset has a very high probability of being a false positive.


The fusion gene pair RET--PTC3 information is not available in ChromothripsisDB database.